BPC-157 and TB-500 Stack: Protocol, Dosage & Complete Guide

Why BPC-157 and TB-500 Are Combined#

BPC-157 and TB-500 are the two most widely used tissue repair peptides, and they work through complementary mechanisms. BPC-157 works primarily through local tissue signalling — it is most effective at the site of injury and is known for its potent effects on tendons, ligaments, gut tissue, and nerve repair. TB-500 (Thymosin Beta-4) works systemically through actin regulation and has a strong anti-inflammatory effect that extends throughout the body. Together, BPC-157 provides targeted repair while TB-500 reduces systemic inflammation and promotes angiogenesis. Most users report synergistic results from the combination.

BPC-157 = local/targeted repair. TB-500 = systemic anti-inflammatory and angiogenesis support.

BPC-157 Overview#

BPC-157 (Body Protection Compound 157) is a pentadecapeptide (15 amino acids) derived from a gastric protective protein. It has been extensively studied in animal models for its healing effects across multiple tissue types. Key researched actions include upregulation of growth hormone receptors in tendon fibroblasts, acceleration of wound closure, protection of gut epithelium, promotion of nerve regeneration, and modulation of dopamine and serotonin pathways. BPC-157 is particularly well-researched for tendon and ligament injuries, where it appears to significantly accelerate recovery. Standard research doses range from 250-500mcg per injection.

TB-500 Overview#

TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide found in high concentrations in platelets and wound fluid. Its primary mechanism is regulation of actin — a protein critical to cell structure, movement, and wound repair. TB-500 promotes angiogenesis, reduces inflammation, improves flexibility and range of motion, and assists in the repair of heart, muscle, tendon, ligament, and skin tissue. It distributes systemically, making it effective for injuries throughout the body regardless of injection site. Standard research doses range from 2-5mg per week during loading.

TB-500 distributes systemically — injection site does not need to be near the injury.

Stack Protocol#

The standard approach uses a loading phase followed by maintenance. Loading phase (weeks 1-4): BPC-157 at 250-500mcg once or twice daily, TB-500 at 5mg twice weekly. Maintenance phase (weeks 5-8+): BPC-157 at 250-500mcg once daily, TB-500 at 2-2.5mg weekly. For acute injuries, some protocols front-load TB-500 more aggressively (5mg 2x/week for the first two weeks). For chronic injuries or general optimisation, a steady protocol without a distinct loading phase is more common.

Dosing and Reconstitution#

Both peptides come as lyophilised powder and must be reconstituted with bacteriostatic water. For BPC-157 (5mg vial): add 2.5mL BAC water → 2mg/mL (2000mcg/mL). A 250mcg dose = 0.125mL = 12.5 units on a U-100 syringe. For TB-500 (5mg vial): add 1mL BAC water → 5mg/mL. A 2.5mg dose = 0.5mL = 50 units. Both can be injected subcutaneously into the abdominal fat. Store reconstituted peptides refrigerated and use within 30 days. Use the Staqk reconstitution calculator to verify your exact draw volumes.

Always use bacteriostatic water — not sterile water. The benzyl alcohol preserves the solution for up to 30 days refrigerated.

Cycle Length and Results#

A standard cycle is 8-12 weeks. For acute injury recovery, an 8-week cycle is typically sufficient for significant improvement. For chronic issues or general optimisation, 12-16 weeks produces more pronounced results. Most users report noticeable improvements in injury recovery, joint pain, and inflammation within 2-4 weeks of starting the loading protocol. Log each injection in your protocol tracker to correlate dose timing with recovery markers.